- 专利标题: PHARMACEUTICAL COMBINATIONS
-
申请号: US17415985申请日: 2019-12-18
-
公开(公告)号: US20210386763A1公开(公告)日: 2021-12-16
- 发明人: Nelson GUERREIRO , Ensar HALILOVIC , Astrid JULLION , Christophe MEILLE , Youzhen WANG
- 申请人: NOVARTIS AG
- 申请人地址: CH Basel
- 专利权人: NOVARTIS AG
- 当前专利权人: NOVARTIS AG
- 当前专利权人地址: CH Basel
- 国际申请: PCT/IB2019/061014 WO 20191218
- 主分类号: A61K31/635
- IPC分类号: A61K31/635 ; A61K31/506 ; A61K45/06 ; A61P35/02
摘要:
The present invention relates to the combination of the HDM2-p53 interaction inhibitor drug (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one [HDM201] and the BCL2 inhibitor 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(3-nitro-4-{[(oxan-4yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide [venetoclax]. The present invention further relates to the use of said combination in the treatment of cancer, in particular hematological tumors. The present invention further relates to dose and dosing regimen related to this combination cancer treatment.